Simulation output for your selection:
Mechanism: Romo is injected subcutaneously once a month. It binds sclerostin which is a major regulator of bone modelling and thus increases formation and decreases resorption, the perfect combination. However the effect of romosozumab is attenuated after approximately a year. This is probably because the Wnt pathway which controls the reaction of bone cells to loads adapts to the new low sclerostin levels.
This is not the best combination of treatment and exercise level for this osteoporotic patient. Try again!